Inflammatory arthritis complicating mogamulizumab treatment of Sézary syndrome
Author:
Affiliation:
1. Department of Rheumatology, Hospital for Special Surgery , New York City, NY, USA
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/kead551/52308916/kead551.pdf
Reference6 articles.
1. Mogamulizumab forecast: clearer patients, with a slight chance of immune mayhem;Larocca;Clin Cancer Res,2019
2. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome;Ni;Clin Cancer Res,2015
3. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial;Kim;Lancet Oncol,2018
4. Dermatologic events associated with the anti-ccr4 antibody mogamulizumab: characterization and management;Musiek;Dermatol Ther,2022
5. How regulatory T cells work;Vignali;Nat Rev Immunol,2008
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3